Patients have routine access to more cancer drugs as prices drop, according to NICE

The National Institute for Health and Care Excellence (NICE) reported last week that patients will have routine access to more cancer drugs as pharmaceutical companies reduce their prices as a result of being reconsidered by NICE in a new approach to the appraisal and funding of cancer drugs in England (a reformed Cancer Drugs Fund (CDF) […]

read more

Cabozantinib NOT recommended by NICE for advanced kidney cancer

We are disappointed to learn that the National Institute for Health and Care Excellence (NICE) have issued draft guidance not to recommend cabozantinib (Cabometyx®) as a second-line treatment for metastatic kidney cancer, despite it’s proven effectiveness at prolonging the overall survival of previously treated kidney cancer patients compared to everolimus. In their Appraisal Consultation Document […]

read more

Combination therapy is promising for kidney cancer

In recent years, drugs that target the vascular endothelial growth factor (VEGF) pathway, such as Sutent (sunitinib), Votrient (pazopanib), Nexavar (sorafenib), Inlyta (axitinib) and Avastin (bevacizumab), have been successful at improving the life expectancy of patients with metastatic renal cell carcinoma (RCC). However, for many patients anti-VEGF therapy fails and their disease eventually progresses. Immunotherapies, […]

read more

Leading kidney cancer specialist talks about nivolumab versus everolimus

In the following video, Dr Robert J. Motzer from Memorial Sloan Kettering Cancer Center, in the USA, and a leading kidney cancer specialist in the world, discusses nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC). This was first published on the OncLive website here.

read more

Everolimus (Afinitor) recommended by NICE for use by NHS England for advanced kidney cancer that has been previously treated

Everolimus (Afinitor) has been recommended by the National Institute for Health and Care Excellence (NICE) for use by NHS England for people with advanced renal cell carcinoma (RCC) that has progressed during or after treatment with a vascular endothelial growth factor (VEGF) targeted therapy. This decision has been made following a reconsideration of everolimus by […]

read more

Side effects to mTOR drugs could be used as biological markers of efficacy in kidney cancer

A recent study published online in BioMed Central Cancer shows how the presence and onset rate of side effects to treatment with mTOR inhibitors, such as everolimus, is associated with tumour response and progression free survival. From 2007 to 2011, metabolic toxicities were collected retrospectively from patients treated with an mTOR inhibitor (everolimus, temsirolimus) for […]

read more

New drug shows promise in kidney cancer in combination with everolimus

A new drug that targets a key enzyme that cancer cells need to keep them alive has been shown to be effective at controlling clear cell and papillary renal cell carcinoma (RCC) when given in combination with the mTOR inhibitor, everolimus. The results from a phase I clinical trial with the new drug, CB-839, were […]

read more

Everolimus provides some benefit for people with papillary renal cell cancer

A study published in the European Journal of Cancer shows that first-line treatment with everolimus provides some clinical benefit to patients with metastatic papillary renal cell carcinoma (pRCC). Treatment options are limited for these patients, which account for 10% to 15% of RCC cases. The open-label phase 2 RAPTOR trial enrolled 92 previously untreated type 1 or type 2 […]

read more

Eisai has started phase III clinical trial with lenvatinib as a potential first-line treatment for advanced kidney cancer

This week saw the initiation of a global phase III clinical trial of lenvatinib, a multiple receptor tyrosine kinase inhibitor, in combination with everolimus and the anti-PD-1 antibody, pembrolizumab, as a potential first-line treatment for advanced renal cell carcinoma (RCC). The trial is called the CLEAR study, and is being run by the Japanese pharmaceutical company, Eisai. […]

read more

European Commission approves Kisplyx (lenvatinib) for advanced kidney cancer

The European Commission has approved Kisplyx (lenvatinib) for the treatment of people with advanced renal cell carcinoma (RCC). Lenvatinib is a new, more potent tyrosine kinase inhibitor, that is given in combination with everolimus for the treatment of people with advanced RCC following the failure of one prior vascular endothelial growth factor (VEGF) targeted therapy. Lenvatinib […]

read more
Showing 31 to 40 of 46 results
  TOP